Drug intelligence / Profile preview

Silfamin

Development stage: Phase 2
Lead developer: Dexa Medica
Administration: Oral

Overview

Silfamin is an herbal medicine developed by PT Dexa Medica and approved in Indonesia for the treatment of infectious and respiratory diseases, specifically the common cold and pharyngitis. It is marketed under the brand name Herbacold. The precise mechanism of action and active botanical ingredients are not specified in public sources. Clinical studies have evaluated its efficacy and safety for symptomatic relief in patients with common cold, using a regimen of 2 tablets (150 mg each) twice daily over three days[1][2].

Brand names: HerbacoldSilfamin
Other names: SilfaminHerbacold

Beyond the preview

Go deeper on Silfamin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Silfamin.

Explore the full profile